LCA2 Gene Therapy Shows Visual, Retinal Improvements at Low Doses
No serious adverse events or significant retinal atrophy occurred.
HG004 (AAV9-hRPE65; HuidaGene)
Updated data from the phase 1 LIGHT study (NCT06088992) of HG004 were presented at
“We saw substantial restoration of vision in patients living with Leber congenital amaurosis who have no treatment options currently in China,” senior author Prof. Peiquan Zhao, Director of OphthalmologyDepartment, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, said in a statement about the updated data.2 “After only a single, one-time administration,all of the patients given HG004 had improvement in retinal sensitivity and there were no serious adverse events, including retinal detachment, have been observed. This trial data of the ‘LIGHT’ study is the first time been discussed in an oral presentation at an international conference. As the principal investigator of the study, I am committed to working with global stakeholders to bring this safe and effective treatment to patients with LCA and bring light to patients with ophthalmic diseases worldwide.”
Investigators have dosed 9 participants (4 adults, 5 children) in the LIGHT study as of the cutoff date in December 2023, 3 each in 3 cohorts evaluating low-dose, mid-dose, and high-dose HG004. No serious adverse events (AEs), signs of inflammation, acute renal toxicity, or clinically determined immune responses have been observed. There have also been no severe ocular surgery complications and most AEs were mild, transient, and spontaneously resolved.1
Participants had no significant or progressive retinal atrophy. Preliminary efficacy findings evaluating best-corrected visual acuity (BCVA), full-field stimulus threshold (FST), and kinetic visual field (KVF) tests were promising, with these measures improving by an average of +11 letters, -2.268 log10cd*s/m2, and +554.25 deg2 (1114e) respectively at 6 months post-treatment. The average BCVA improvement was +14.3 letters at 2 months and +7.5 letters at 3 months post injection; the average FST improvement was –2.774 log10cd*s/m2 at 2 months and –1.413 log10cd*s/m2 at 3 months post injection; and the average KVF improvement was +817.17 deg2 (1114e) at 2 months and +958.30 deg2 (1114e) at 3 months post injection. Most participants had at least a 2-log unit increase in pupillary light responses. Notably, the poster emphasized that these dose levels are 1/25 to 1/15 folds lower than approved gene therapies for LCA2.1
“We look forward to sharing recent progress in preclinical and clinical data on our HG202 CRISPR RNA-targeting therapy program for AMD and HG004 gene replacement therapy program for LCA2 which has been granted both orphan drug and rare pediatric disease designations for inherited retinal dystrophies associated with RPE65 mutations by the U.S. FDA,” Alvin Luk, PhD, MBA, CCRA, cofounder and CEO, HuidaGene, commented in a recent statement.2
REFERENCES
1. Fei P, Yang Y, Peng J, et al. Preliminary Safety and Efficacy of HG004 Gene Therapy Trial for Leber's Congenital Amaurosis Associated with Mutations in RPE65 Gene. Presented at: ASGCT 27th Annual Meeting, May 7-10; Baltimore, Maryland. Abstract #915
2. HuidaGene Orally Presents Data Highlighting Strength of Ophthalmology Portfolio at the 2024 Association for Research in Visual and Ophthalmology Annual Meeting. News release. HudaGene. April 22, 2024. https://www.huidagene.com/new/news/56
Newsletter
Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.
Related Articles
- Around the Helix: Cell and Gene Therapy Company Updates – September 17, 2025
September 17th 2025
- Top News in Lymphoma Cell Therapy for World Lymphoma Awareness Day 2025
September 15th 2025